CICC: Maintains Buy Rating on China Medical System Holdings (02373), Raises Target Price to HKD 40

According to the financial news app, Zhijun released a research report stating that the profit forecast for Meilitianyuan Medical Health (02373) for 2025-2026 remains unchanged. The current stock price corresponds to a P/E ratio of 25/21x for 2025-2026. The recommendation to outperform the industry is maintained, based on the company's outstanding business model advantages and the opening up of internal and external growth potential in the medium to long term. The target price has been raised by 8% to HK$40, corresponding to a P/E ratio of 31/27x for 2025-2026, with a 21% upside potential.